Pharming Group N.V.
Pharming Group N.V. (PHGUF) Financial Performance & Income Statement Overview
Review Pharming Group N.V. (PHGUF) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Pharming Group N.V. (PHGUF) Income Statement & Financial Overview
Explore comprehensive income reports for Pharming Group N.V. PHGUF, broken down by year and quarter.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $79.09M | $92.67M | $75.06M | $74.03M |
| Cost of Revenue | $8.32M | $12.21M | $6.84M | $7.99M |
| Gross Profit | $70.77M | $80.46M | $68.22M | $66.04M |
| Gross Profit Ratio | $0.89 | $0.87 | $0.91 | $0.89 |
| R&D Expenses | $21.14M | $22.31M | $20.72M | $21.58M |
| SG&A Expenses | $57.06M | -$38.65M | $43.98M | $48.45M |
| Operating Expenses | $77.81M | $73.75M | $63.92M | $70.03M |
| Total Costs & Expenses | $86.14M | $85.97M | $70.74M | $78.03M |
| Interest Income | $604000.00 | $1.10M | $825000.00 | $920000.00 |
| Interest Expense | $5.10M | $1.25M | $3.00M | $1.97M |
| Depreciation & Amortization | $2.58M | $7.70M | $2.74M | -$293000.00 |
| EBITDA | -$4.11M | $15.63M | $7.25M | -$4.28M |
| EBITDA Ratio | -$0.05 | $0.17 | $0.10 | -$0.06 |
| Operating Income | -$7.04M | $6.70M | $4.11M | -$4.00M |
| Operating Income Ratio | -$0.09 | $0.07 | $0.05 | -$0.05 |
| Other Income/Expenses (Net) | -$4.74M | -$26000.00 | -$2.59M | $3.06M |
| Income Before Tax | -$11.79M | $6.68M | $1.51M | $299719.00 |
| Income Before Tax Ratio | -$0.15 | $0.07 | $0.02 | $0.004 |
| Income Tax Expense | $3.10M | $3.82M | $2.55M | $1.10M |
| Net Income | -$14.72M | $2.86M | -$1.03M | -$1.20M |
| Net Income Ratio | -$0.19 | $0.03 | -$0.01 | -$0.02 |
| EPS | -$0.02 | $0.005 | -$0.002 | -$0.001 |
| Diluted EPS | -$0.02 | $0.005 | -$0.002 | -$0.001 |
| Weighted Avg Shares Outstanding | $669.05M | $740.00M | $646.25M | $847.94M |
| Weighted Avg Shares Outstanding (Diluted) | $669.05M | $740.00M | $646.25M | $847.94M |
Over the past four quarters, Pharming Group N.V. demonstrated steady revenue growth, increasing from $74.03M in Q2 2024 to $79.09M in Q1 2025. Operating income reached -$7.04M in Q1 2025, maintaining a consistent -9% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$4.11M, reflecting operational efficiency. Net income dropped to -$14.72M, with EPS at -$0.02. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan